Format

Send to

Choose Destination
See comment in PubMed Commons below
Biol Blood Marrow Transplant. 2013 Nov;19(11):1546-56. doi: 10.1016/j.bbmt.2013.07.017. Epub 2013 Jul 23.

Pulmonary hypertension after hematopoietic stem cell transplantation.

Author information

1
Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. Electronic address: christopher.dandoy@cchmc.org.

Abstract

Pulmonary hypertension (PH) is a potentially fatal complication of hematopoietic stem cell transplantation (HSCT). Given its nonspecific clinical presentation, it is likely that this clinical entity is underdiagnosed after HSCT. Data describing the incidence, risk factors, and etiology of PH in HSCT recipients are minimal. Physicians caring for HSCT recipients should be aware of this severe post-transplant complication because timely diagnosis and treatment may allow improved clinical outcomes. We summarize the pathophysiology, clinical presentation, diagnosis, and management of PH in HSCT recipients.

KEYWORDS:

Pulmonary arterial hypertension; Pulmonary hypertension; Pulmonary veno-occlusive disease; Thrombotic microangiopathy

PMID:
23891748
DOI:
10.1016/j.bbmt.2013.07.017
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center